PURPOSE: This phase II study (S0341) evaluated the efficacy and tolerability of single-agent erlotinib in unselected chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) of 2. Exploratory analyses of a number of biomarkers relating to epidermal growth factor receptor pathway activation were also performed. PATIENTS AND METHODS: Patients with stage IIIB (pleural effusion) or stage IV NSCLC with a PS of 2 and no prior chemotherapy or biologic treatment for NSCLC received erlotinib 150 mg daily. RESULTS: A total of 81 patients entered the study; 76 were assessable. One complete and 5 partial responses were noted for an overall response rate of 8% (95% CI 3%-16%). Stable disease (SD) was seen in 26 patients (34%) resulting in a disease control rate (DCR = CR/PR/SD) of 42%. Progression free and median survival were 2.1 months (95% CI 1.5-3.1) and 5 months (95% CI 3.6-7.2), respectively. One-year survival was 24% (95% CI 15%-34%). Although treatment was generally well tolerated, grade 3 to 4 toxicity was reported in 30 patients (40%), including fatigue (16%), rash (9%), diarrhea (7%), and anorexia (7%). There was one possible treatment related death (pneumonitis). CONCLUSIONS: In chemotherapy-naive patients with advanced NSCLC and a PS of 2, single agent erlotinib resulted in an acceptable but significant level of treatment-related side effects. With an overall DCR of 42% and median survival of 5 months, results are comparable to those achieved with chemotherapy in this population. Development of an epidermal growth factor receptor-directed biomarker selection strategy may optimize use of erlotinib in PS 2 patients.
PURPOSE: This phase II study (S0341) evaluated the efficacy and tolerability of single-agent erlotinib in unselected chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) of 2. Exploratory analyses of a number of biomarkers relating to epidermal growth factor receptor pathway activation were also performed. PATIENTS AND METHODS: Patients with stage IIIB (pleural effusion) or stage IV NSCLC with a PS of 2 and no prior chemotherapy or biologic treatment for NSCLC received erlotinib 150 mg daily. RESULTS: A total of 81 patients entered the study; 76 were assessable. One complete and 5 partial responses were noted for an overall response rate of 8% (95% CI 3%-16%). Stable disease (SD) was seen in 26 patients (34%) resulting in a disease control rate (DCR = CR/PR/SD) of 42%. Progression free and median survival were 2.1 months (95% CI 1.5-3.1) and 5 months (95% CI 3.6-7.2), respectively. One-year survival was 24% (95% CI 15%-34%). Although treatment was generally well tolerated, grade 3 to 4 toxicity was reported in 30 patients (40%), including fatigue (16%), rash (9%), diarrhea (7%), and anorexia (7%). There was one possible treatment related death (pneumonitis). CONCLUSIONS: In chemotherapy-naive patients with advanced NSCLC and a PS of 2, single agent erlotinib resulted in an acceptable but significant level of treatment-related side effects. With an overall DCR of 42% and median survival of 5 months, results are comparable to those achieved with chemotherapy in this population. Development of an epidermal growth factor receptor-directed biomarker selection strategy may optimize use of erlotinib in PS 2patients.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: C J Sweeney; J Zhu; A B Sandler; J Schiller; C P Belani; C Langer; J Krook; D Harrington; D H Johnson Journal: Cancer Date: 2001-11-15 Impact factor: 6.860
Authors: Rogerio C Lilenbaum; James E Herndon; Marcy A List; Chris Desch; Dorothy M Watson; Antonius A Miller; Stephen L Graziano; Michael C Perry; Wayne Saville; Philippe Chahinian; Jane C Weeks; Jimmie C Holland; Mark R Green Journal: J Clin Oncol Date: 2005-01-01 Impact factor: 44.544
Authors: C Gridelli; A Ardizzoni; T Le Chevalier; C Manegold; F Perrone; N Thatcher; N van Zandwijk; M Di Maio; O Martelli; F De Marinis Journal: Ann Oncol Date: 2004-03 Impact factor: 32.976
Authors: Primo N Lara; James Moon; Paul J Hesketh; Mary W Redman; Stephen K Williamson; Wallace L Akerley; Fred R Hirsch; Philip C Mack; David R Gandara Journal: J Thorac Oncol Date: 2015-12-25 Impact factor: 15.609
Authors: A C Mita; K Papadopoulos; M J A de Jonge; G Schwartz; J Verweij; M M Mita; A Ricart; Q S-C Chu; A W Tolcher; L Wood; S McCarthy; M Hamilton; K Iwata; B Wacker; K Witt; E K Rowinsky Journal: Br J Cancer Date: 2011-08-30 Impact factor: 7.640